Table 2.
Base Case Results for an Analysis of Baseline Genotype Compared to No Baseline Genotype at Human Immunodeficiency Virus Diagnosis
| Cohort | Strategy | Undiscounted | Discounted | |||||
|---|---|---|---|---|---|---|---|---|
| QALYs | ∆ QALDsa | QALYs | ∆ QALYs | Cost ($) | ∆ ($) | Incremental Cost-effectiveness Ratio ($/QALY) | ||
| All people with human immunodeficiency virus | No baseline genotype | 27.959 | <1 | 16.152 | 620 200 | |||
| Baseline genotype | 27.962 | 16.153 | 0.001 | 620 700 | 500 | 420 000 | ||
| Subgroup | ||||||||
| No transmitted drug resistance (83.8%) | No baseline genotype | 27.962 | … | … | … | … | … | |
| Baseline genotype | 27.962 | 0 | … | … | … | … | … | |
| Nucleoside reverse transcriptase inhibitors resistance (5.8%) | No baseline genotype | 27.926 | … | … | … | … | … | |
| Baseline genotype | 27.962 | 13 | … | … | ||||
| Nonnucleoside reverse transcriptase inhibitors resistance (7.2%) | No baseline genotype | 27.960 | … | … | … | … | … | |
| Baseline genotype | 27.962 | <1 | … | … | … | … | … | |
| Protease inhibitors resistance (3.2%) | No baseline genotype | 27.962 | … | … | … | … | … | |
| Baseline genotype | 27.962 | 0 | … | … | … | … | … |
Abbreviations: QALY, quality-adjusted life-years; QALDs, quality-adjusted life-days.
aDifferences in life expectancy between the 2 strategies are small, so we report these differences in QALDs.